Ketamine for Low Mood States in the ER

Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01209845

Enrollment

Registered

2010-09-27

Start date

2010-04-30

Completion date

2010-12-31

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Suicide Ideation

Keywords

depression, suicide ideation, emergency department, ketamine

Brief summary

The investigators hope to see if a commonly used drug such as ketamine could help depressed ER patients feel better and improve their mood quickly.

Detailed description

Rapid-onset antidepressants could have important clinical impact if their benefits extended to Emergency Department (ED) patients. We hope to explore the preliminary feasibility, tolerability and efficacy of single-dose, intravenous (IV) ketamine in depressed ED patients who presented with suicide ideation (SI). The manuscript (article) for this study has been retracted because Yale University conducted an investigation that determined that the description of the research was not accurate. The article misrepresents both the protocol-specified doses and the actual delivered doses of ketamine.

Interventions

DRUGketamine

intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults (\>18yrs) presenting to the Emergency department with symptoms of depression and/or suicide ideation (MADRS\>30) with ability to give informed consent. * medically stable

Exclusion criteria

* psychosis, bipolar, or other significant physical or mental illness * pregnancy * non-voluntary status * urine drug screen positive for drugs of abuse

Design outcomes

Primary

Measure	Time frame	Description
Montgomery Asberg Depression Rating Scale (MADRS)	40, 80, 120, 240 minutes after administration of drug	The MADRS measures mood (depression) and item 10 measures suicide ideation.

Secondary

Measure	Time frame	Description
recruitment success and retention of subjects in the ER	initial recruitment of eligible subjects in the ER and for two weeks after administration of drug	All patient subjects are admitted and we will follow them in the hospital and for 2 weeks after hospital discharge.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026